Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease

Inclusion Criteria:

- Meets National Institute of Neurological and Communicative Disorders and
Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria
for probable Alzheimer's Disease

- Has completed participation in solanezumab Study LZAM or Study LZAN through 80 weeks

- Must continue to have a reliable caregiver who is in frequent contact with the patient
for the entire study

- Must have good vein access to administer infusions

- Agrees not to participate in studies of any other investigational compounds for the
duration of their participation in Study LZAO

Exclusion Criteria:

- Are currently enrolled in, or discontinued within the last 30 days from, a clinical
trial involving an investigational drug or device or off-label use of a drug or device
(other than the study drug/device used in this study), or concurrently enrolled in any
other type of medical research judged not to be scientifically or medically compatible
with this study

- Meets LZAM or LZAN discontinuation criteria at the end of treatment in LZAM or LZAN
study